Clostridium difficile infection in older adults

Aging Health

Volumn 9, Issue 4, 2013, Pages 403-414

  Jump, Robin L P ^a,b  

^a LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

aging; antimicrobial stewardship; Clostridium difficile infection; fecal bacteriotherapy; fidaxomicin; infection control; long term care facilities; metronidzole; older adults; vancomycin

Indexed keywords

ALBUMIN; ANTIBIOTIC AGENT; CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; DICLOFENAC; FIDAXOMICIN; METRONIDAZOLE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; VANCOMYCIN;

AGE; AGED; AGING; ANTIBIOTIC RESISTANCE; ARTIFICIAL VENTILATION; BIOLOGICAL THERAPY; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; COLON PERFORATION; COLON RESECTION; DISEASE SEVERITY; DISINFECTION; DRUG EXPOSURE; FECAL TRANSPLANTATION; HEALTH CARE SYSTEM; HEALTH CARE UTILIZATION; HOSPITAL ADMISSION; HOSPITAL HYGIENE; HOSPITAL INFECTION; HUMAN; HYPOALBUMINEMIA; INFECTION CONTROL; INTESTINE FLORA; PATHOGENESIS; PREVALENCE; REVIEW; RISK FACTOR; SMOKING; STOMACH ACID; TREATMENT OUTCOME; UNITED STATES;

EID: 84881460675     PISSN: 1745509X     EISSN: 17455103     Source Type: Journal    
DOI: 10.2217/ahe.13.37     Document Type: Review

References (97)

1. Lawley TD, Walker AW. Intestinal colonization resistance. Immunology 138, 1-11 (2013
2. Kuehne SA, Cartman ST, Minton NP. Both, toxin A and toxin B, are important in Clostridium difficile infection. Gut Microbes 2, 252-255 (2011
3. al-Barrak A, Embil J, Dyck B et al. An outbreak of toxin A negative, toxin B positive Clostridium difficile-associated diarrhea in a Canadian tertiary-care hospital. Can. Commun. Dis. Rep. 25, 65-69 (1999
4. Lyras D, O'Connor JR, Howarth PM et al. Toxin B is essential for virulence of Clostridium difficile. Nature 458, 1176-1179 (2009
5. Kuehne SA, Cartman ST, Heap JT, Kelly ML, Cockayne A, Minton NP. The role of toxin A and toxin B in Clostridium difficile infection. Nature 467, 711-713 (2010
6. Loo VG, Poirier L, Miller MA et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N. Engl. J. Med. 353, 2442-2449 (2005
7. McDonald LC, Killgore GE, Thompson A et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N. Engl. J. Med. 353, 2433-2441 (2005
8. Goorhuis A, Bakker D, Corver J et al. Emergence of Clostridium difficile infection due to a new hypervirulent strain, polymerase chain reaction ribotype 078. Clin. Infect. Dis. 47, 1162-1170 (2008
9. Vardakas KZ, Konstantelias AA, Loizidis G, Rafailidis PI, Falagas ME. Risk factors for development of Clostridium difficile infection due to BI/NAP1/027 strain: A meta-analysis. Int. J. Infect. Dis. 16, e768-e773 (2012
10. Bacci S, Mølbak K, Kjeldsen MK, Olsen KEP. Binary toxin and death after Clostridium difficile infection. Emerging Infect. Dis. 17, 976-982 (2011
11. Warny M, Pepin J, Fang A et al Toxin production by an emerging strain of Clostridium difficile associated with outbreaks toxin production by an emerging strain of severe disease in North America and Europe. Lancet 366, 1079-1084 (2005
12. Cartman ST, Kelly ML, Heeg D, Heap JT, Minton NP. Precise manipulation of the Clostridium difficile chromosome reveals a lack of association between the tcdC genotype and toxin production. Appl. Environ. Microbiol. 78, 4683-4690 (2012
13. Gould CV, McDonald LC. Bench-to-bedside review: Clostridium difficile colitis. Crit. Care 12, 203 (2008
14. Adams DA, Riggs MM, Donskey CJ. Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic Clostridium difficile strains in the cecal contents of mice. Antimicrob. Agents Chemother. 51, 2674-2678 (2007
15. Labbé A-C, Poirier L, Maccannell D et al. Clostridium difficile infections in a Canadian tertiary care hospital before and during a regional epidemic associated with the BI/NAP1/027 strain. Antimicrob. Agents Chemother. 52, 3180-3187 (2008
16. He M, Miyajima F, Roberts P et al. Emergence and global spread of epidemic healthcare-associated Clostridium difficile. Nature Genetics 45, 109-113 (2013
17. Sirard S, Valiquette L, Fortier L-C. Lack of association between clinical outcome of Clostridium difficile infections, strain type, and virulence-associated phenotypes. J. Clin. Microbiol. 49, 4040-4046 (2011
18. Wilcox MH, Shetty N, Fawley WN et al. Changing epidemiology of Clostridium difficile infection following the introduction of a national ribotyping-based surveillance scheme in England. Clin. Infect. Dis. 55, 1056-1063 (2012
19. Lucado J, Gould C, Elixhauser A. Clostridium difficile Infections (CDI) In Hospital Stays, 2009 - Healthcare Cost and Utilization Project (HCUP) Statistical Briefs. NCBI bookshelf. Agency for Healthcare Research and Quality, Rockville, MD, USA (2006
20. McDonald LC, Lessa F, Sievert D et al. Vital signs: Preventing Clostridium difficile infections. MMWR Morb. Mortal Wkly Rep. 61(9), 157-162 (2012
21. Cohen SH, Gerding DN, Johnson S et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect. Control Hosp. Epidemiol. 31, 431-455 (2010
22. Dumyati G, Stevens V, Hannett GE et al. Community-associated Clostridium difficile infections, Monroe County, New York, USA. Emerg. Infect. Dis. 18, 392-400 (2012
23. Kutty PK, Woods CW, Sena AC et al. Risk factors for and estimated incidence of community-associated Clostridium difficile infection, North Carolina, USA. Emerg. Infect. Dis. 16, 197-204 (2010
24. Khanna S, Pardi DS, Aronson SL et al. The epidemiology of community-acquired Clostridium difficile infection: A population-based study. Am. J. Gastroenterol. 107, 89-95 (2012
25. Jones AM, Kuijper EJ, Wilcox MH. Clostridium difficile: A European perspective. J. Infect. 66, 115-128 (2013
26. Campbell RJ, Giljahn L, Machesky K et al. Clostridium difficile infection in Ohio hospitals and nursing homes during 2006. Infect. Control Hosp. Epidemiol. 30, 526-533 (2009
27. Health Protection Agency. Quarterly Epidemiological Commentary: Mandatory MRSA, MSSA and E. coli Bacteraemia, and C. Difficile Infection Data (up to July-September 2012). Health Protection Agency, London, UK (2012
28. Wilcox MH, Shetty N, Fawley WN et al. Changing epidemiology of Clostridium difficile infection following the introduction of a national ribotyping-based surveillance scheme in England. Clin. Infect. Dis. 55, 1056-1063 (2012
29. Loo VG, Bourgault A-M, Poirier L et al. Host and pathogen factors for Clostridium difficile infection and colonization. N. Engl. J. Med. 365, 1693-1703 (2011
30. Dial S, Delaney JA, Barkun AN, Suissa S. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 294, 2989-2995 (2005
31. Tleyjeh IM, Abdulhak AA, Riaz M et al. The association between histamine 2 receptor antagonist use and Clostridium difficile infection: A systematic review and meta-analysis. PLoS ONE 8, e56498 (2013
32. Dial S, Alrasadi K, Manoukian C, Huang A, Menzies D. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: Cohort and case-control studies. CMAJ 171, 33-38 (2004
33. Khanna S, Aronson SL, Kammer PP, Baddour LM, Pardi DS. Gastric acid suppression and outcomes in Clostridium difficile infection: A population-based study. Mayo Clin. Proc. 87, 636-642 (2012
34. Jump RLP, Pultz MJ, Donskey CJ. Vegetative Clostridium difficile survives in room air on moist surfaces and in gastric contents with reduced acidity: A potential mechanism to explain the association between proton pump inhibitors and C. difficile-associated diarrhea? Antimicrob. Agents Chemother. 51, 2883-2887 (2007
35. Nerandzic MM, Pultz MJ, Donskey CJ. Examination of potential mechanisms to explain the association between proton pump inhibitors and Clostridium difficile infection. Antimicrob. Agents Chemother. 53, 4133-4137 (2009
36. Rogers MAM, Greene MT, Saint S et al. Higher rates of Clostridium difficile infection among smokers. PLoS ONE 7, e42091 (2012
37. Naggie S, Miller BA, Zuzak KB et al. A case-control study of community-associated Clostridium difficile infection: No role for proton pump inhibitors. Am. J. Med. 124(3), 276.e1-7 (2011
38. Motzkus-Feagans CA, Pakyz A, Polk R, Gambassi G, Lapane KL. Statin use and the risk of Clostridium difficile in academic medical centres. Gut 61, 1538-1542 (2012
39. Songer JG, Trinh HT, Killgore GE, Thompson AD, McDonald LC, Limbago BM. Clostridium difficile in retail meat products, USA, 2007. Emerg. Infect. Dis. 15, 819-821 (2009
40. Curry SR, Marsh JW, Schlackman JL, Harrison LH. Prevalence of Clostridium difficile in uncooked ground meat products from Pittsburgh, Pennsylvania. Appl. Environ. Microbiol. 78, 4183-4186 (2012
41. Limbago B, Thompson AD, Greene SA et al. Development of a consensus method for culture of Clostridium difficile from meat and its use in a survey of US retail meats. Food Microbiol. 32, 448-451 (2012
42. Dharmarajan T, Sipalay M, Shyamsundar R, Norkus E, Pitchumoni C. Co-morbidity, not age predicts adverse outcome in Clostridium difficile colitis. World J. Gastroenterol. 6, 198-201 (2000
43. McFarland LV, Mulligan ME, Kwok RY, Stamm WE. Nosocomial acquisition of Clostridium difficile infection. N. Engl. J. Med. 320, 204-210 (1989
44. Sitzlar B, Vajravelu RK, Jury L, Donskey CJ, Jump RLP. Environmental decontamination with ultraviolet radiation to prevent recurrent Clostridium difficile infection in 2 roommates in a long-term care facility. Infect. Control Hosp. Epidemiol. 33, 534-536 (2012
45. Guerrero DM, Nerandzic MM, Jury LA, Jinno S, Chang S, Donskey CJ. Acquisition of spores on gloved hands after contact with the skin of patients with Clostridium difficile infection and with environmental surfaces in their rooms. Am. J. Infect. Control 40, 556-558 (2012
46. Jones AL, Dwyer LL, Bercovitz AR, Strahan GW. The National Nursing Home Survey: 2004 overview. Vital Health Stat. (167), 1-155 (2009
47. Guerrero DM, Nerandzic MM, Jury LA, Chang S, Jump RL, Donskey CJ. Clostridium difficile infection in a department of veterans affairs long-term care facility. Infect. Control Hosp. Epidemiol. 32, 513-515 (2011
48. Loeb MB, Craven S, McGeer AJ et al. Risk factors for resistance to antimicrobial agents among nursing home residents. Am. J. Epidemiol. 157, 40 -47 (2003
49. Trick WE, Weinstein RA, DeMarais PL et al. Comparison of routine glove use and contact-isolation precautions to prevent transmission of multidrug-resistant bacteria in a long-term care facility. J. Am. Geriatr. Soc. 52, 2003-2009 (2004
50. Loeb M, Simor AE, Landry L et al. Antibiotic use in Ontario facilities that provide chronic care. J. Gen. Intern. Med. 16, 376-383 (2001
51. Nicolle LE, Bentley DW, Garibaldi R, Neuhaus EG, Smith PW. Antimicrobial use in long-term-care facilities. Infect. Control Hosp. Epidemiol. 21, 537-545 (2000
52. Peron EP, Hirsch AA, Jury LA, Jump RLP, Donskey CJ. Another setting for stewardship: High rate of unnecessary antimicrobial use in a veterans affairs long-term care facility. J. Am. Geriatr. Soc. 61, 289-290 (2013
53. Kelly CP. Can we identify patients at high risk of recurrent Clostridium difficile infection? Clin. Microbiol. Infect. 18(Suppl. 6), 21-27 (2012
54. Borriello SP, Barclay FE. An in-vitro model of colonisation resistance to Clostridium difficile infection. J. Med. Microbiol. 21, 299-309 (1986
55. Hopkins MJ, Macfarlane GT. Changes in predominant bacterial populations in human faeces with age and with Clostridium difficile infection. J. Med. Microbiol. 51, 448-454 (2002
56. Rea MC, O'Sullivan O, Shanahan F et al. Clostridium difficile carriage in elderly subjects and associated changes in the intestinal microbiota. J. Clin. Microbiol. 50, 867-875 (2012
57. Biagi E, Nylund L, Candela M et al. Through ageing, and beyond: Gut microbiota and inflammatory status in seniors and centenarians. PLoS ONE 5, e10667 (2010
58. Kyne L, Merry C, O'Connell B, Kelly A, Keane C, O'Neill D. Factors associated with prolonged symptoms and severe disease due to Clostridium difficile. Age Ageing 28, 107-113 (1999
59. Simor AE, Bradley SF, Strausbaugh LJ, Crossley K, Nicolle LE. Clostridium difficile in long-term-care facilities for the elderly. Infect. Control Hosp. Epidemiol. 23, 696-703 (2002
60. Centers for Disease Control and Prevention (CDC). Severe Clostridium difficile-associated disease in populations previously at low risk - four states, 2005. MMWR Morb. Mortal. Wkly Rep. 54, 1201-1205 (2005
61. Henrich TJ, Krakower D, Bitton A, Yokoe DS. Clinical risk factors for severe Clostridium difficile-associated disease. Emerg. Infect. Dis. 15, 415-422 (2009
62. Elixhauser A, Steiner C, Gould C. Readmissions following hospitalizations with Clostridium difficile infections, 2009. HCUP Statistical brief #145. Agency for Healthcare Research and Quality, Rockville, MD, USA (2012
63. Louie TJ, Miller MA, Crook DW et al. Effect of age on treatment outcomes in Clostridium difficile infection. J. Am. Geriatr. Soc. 61, 222-230 (2013
64. Hu MY, Katchar K, Kyne L et al. Prospective derivation and validation of a clinical prediction rule for recurrent Clostridium difficile infection. Gastroenterology 136, 1206-1214 (2009
65. Garey KW, Sethi S, Yadav Y, DuPont HL. Meta-analysis to assess risk factors for recurrent Clostridium difficile infection. J. Hosp. Infect. 70, 298-304 (2008
66. Bauer MP, Kuijper EJ, Van Dissel JT. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): Treatment guidance document for Clostridium difficile infection (CDI). Clin. Microbiol. Infect. 15, 1067-1079 (2009
67. Cober ED, Malani PN. Clostridium difficile infection in the 'oldest' old: Clinical outcomes in patients aged 80 and older. J. Am. Geriatr. Soc. 57, 659-662 (2009
68. Tannock GW, Munro K, Taylor C et al. A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin. Microbiology 156, 3354-3359 (2010
69. Louie TJ, Miller MA, Mullane KM et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N. Engl. J. Med. 364, 422-431 (2011
70. Petrella LA, Sambol SP, Cheknis A et al. Decreased cure and increased recurrence rates for Clostridium difficile infection caused by the epidemic C. difficile BI strain. Clin. Infect. Dis. 55, 351-357 (2012
71. Aas J, Gessert CE, Bakken JS. Recurrent Clostridium difficile colitis: Case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin. Infect. Dis. 36, 580-585 (2003
72. Gough E, Shaikh H, Manges AR. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin. Infect. Dis. 53, 994-1002 (2011
73. Van Nood E, Vrieze A, Nieuwdorp M et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N. Engl. J. Med. 368, 407-415 (2013
74. Rubin TA, Gessert CE, Aas J. Stool transplantation for older patients with Clostridium difficile infection. J. Am. Geriatr. Soc. 57, 2386 (2009
75. Donskey CJ. Preventing transmission of Clostridium difficile: Is the answer blowing in the wind? Clin. Infect. Dis. 50, 1458-1461 (2010
76. Shaughnessy MK, Micielli RL, DePestel DD et al. Evaluation of hospital room assignment and acquisition of Clostridium difficile infection. Infect. Control Hosp. Epidemiol. 32, 201-206 (2011
77. Orenstein R, Aronhalt KC, McManus JE Jr, Fedraw LA. A targeted strategy to wipe out Clostridium difficile. Infect. Control Hosp. Epidemiol. 32, 1137-1139 (2011
78. Manian FA, Griesnauer S, Bryant A. Implementation of hospital-wide enhanced terminal cleaning of targeted patient rooms and its impact on endemic Clostridium difficile infection rates. Am. J. Infect. Control. 41, 537-541 (2013
79. Stone SP, Fuller C, Savage J et al. Evaluation of the national Cleanyourhands campaign to reduce Staphylococcus aureus bacteraemia and Clostridium difficile infection in hospitals in England and Wales by improved hand hygiene: Four year, prospective, ecological, interrupted time series study. BMJ 344, e3005 (2012
80. Dellit TH, Owens RC, McGowan JE et al Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin. Infect. Dis. 44, 159-177 (2007
81. Fishman NO. Antimicrobial Stewardship. Am. J. Med. 119, S53-S61 (2006
82. Ludlam H, Brown N, Sule O, Redpath C, Coni N, Owen G. An antibiotic policy associated with reduced risk of Clostridium difficile-associated diarrhoea. Age Ageing 28, 578-580 (1999
83. Valiquette L, Cossette B, Garant M-P, Diab H, Pépin J. Impact of a reduction in the use of high-risk antibiotics on the course of an epidemic of Clostridium difficile-associated disease caused by the hypervirulent NAP1/027 strain. Clin. Infect. Dis. 45(Suppl. 2), S112-S121 (2007
84. Aldeyab MA, Devine MJ, Flanagan P et al. Multihospital outbreak of Clostridium difficile ribotype 027 infection: Epidemiology and analysis of control measures. Infect. Control Hosp. Epidemiol. 32, 210-219 (2011
85. Jump RLP, Olds DM, Seifi N et al. Effective antimicrobial stewardship in a long-term care facility through an infectious disease consultation service: Keeping a lid on antibiotic use. Infect. Control Hosp. Epidemiol. 33, 1185-1192 (2012
86. Jiang Z-D, Hoang LN, Lasco TM, Garey KW, DuPont HL. Physician attitudes toward the use of fecal transplantation for recurrent Clostridium difficile infection in a metropolitan area. Clin. Infect. Dis. 56, 1059-1060 (2013
87. Surawicz CM, Brandt LJ, Binion DG et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am. J. Gastroenterol. 108, 478-498 (2013
88. Lawley TD, Clare S, Walker AW et al. Targeted restoration of the intestinal microbiota with a simple, defined bacteriotherapy resolves relapsing Clostridium difficile disease in mice. PLoS Pathog. 8, e1002995 (2012
89. Sougioultzis S, Kyne L, Drudy D et al. Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea. Gastroenterology 128, 764-770 (2005
90. Gerding DN. Clostridium difficile infection prevention: Biotherapeutics, immunologics, and vaccines. Discov. Med. 13, 75-83 (2012
91. Hebert C, Du H, Peterson LR, Robicsek A. Electronic health record-based detection of risk factors for Clostridium difficile infection relapse. Infect. Control. Hosp. Epidemiol. 34, 407-414 (2013
92. Eyre DW, Walker AS, Wyllie D, et al. Predictors of first recurrence of Clostridium difficile infection: Implications for initial management. Clin. Infect. Dis. 55(Suppl. 2), S77-S87 (2012
93. Dubberke ER, Reske KA, Yan Y, Olsen MA, McDonald LC, Fraser VJ. Clostridium difficile - Associated disease in a setting of endemicity: Identification of novel risk factors. Clin. Infect. Dis. 45, 1543-1549 (2007
94. Howell MD NV. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch. Intern. Med. 170, 784-790 (2010
95. Vesteinsdottir I, Gudlaugsdottir S, Einarsdottir R, Kalaitzakis E, Sigurdardottir O, Bjornsson ES. Risk factors for Clostridium difficile toxin-positive diarrhea: A population-based prospective case-control study. Eur. J. Clin. Microb. Infect. Dis. 31, 2601-2610 (2012
96. Suissa D, Delaney JAC, Dial S, Brassard P. Non-steroidal anti-inflammatory drugs and the risk of Clostridium difficile-associated disease. Br. J. Clin. Pharmacol. 74, 370-375 (2012
97. Zilberberg MD, Nathanson BH, Sadigov S, Higgins TL, Kollef MH, Shorr AF. Epidemiology and outcomes of Clostridium difficile-associated disease among patients on prolonged acute mechanical ventilation. Chest 136, 752-758 (2009